Possible Protective Effect of Endothelin-1 Receptor Antagonist on Renal Impairment in Type 2 Diabetic Rats | ||||
| Bulletin of Egyptian Society for Physiological Sciences | ||||
| Article 8, Volume 41, Issue 2, April 2021, Page 242-257 PDF (583.57 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/besps.2020.35082.1067 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sohair Saleh1; Eman Ibrahim Elgizawy2; Lamiaa Gharieb  3; sally said donia4
| ||||
| 1physiology department, faculty of medicine, Menoufia university | ||||
| 2physiology departement, faculty of medicine, menoufia university | ||||
| 3physiology department, faculty of medicine, KFS university, Egypt | ||||
| 4physiology departement, menoufia faculty of medicine | ||||
| Abstract | ||||
| Background: Diabetic nephropathy (DN) is characterized by persistent albuminuria and progressive decline in glomerular filtration rate (GFR). Bosentan is a non-peptide mixed antagonist of ET-1. Aim: To investigate the possible protective role of bosentan on renal impairment in T2DM rats and the mechanisms concerned. Materials: Fifty rats were randomly divided into five equal groups; Non-Diabetic (ND), Diabetic non-treated (DN), Diabetic Bosentan-treated (D-Bos.), Diabetic Metformin-treated (D-Met.), Diabetic combined Bosentan and Metformin-treated groups (D-Bos& Met.). T2DM was induced by Streptozotocin (STZ) (35mg/kg) and high fat diet (HFD) for 3 weeks. Both Bosentan and metformin were given orally for 4 weeks. At the end of the experiment, 24hrs urine samples were collected to measure urine (volume, albumin, NAG and creatinine), renal blood flow velocity (RBFV) and peripheral renal resistance (RVR) were measured using Doppler technique. Blood was collected directly from abdominal aorta to estimate fasting serum glucose, glycosylated hemoglobin (HBA1c), serum insulin, complete lipid profile, renal function tests and parameters of oxidative stress: malondialdehyde (MDA), total antioxidant capacity (TAC) and tumor necrosis factor-α (TNFα). Insulin resistance, serum LDL-cholesterol, urinary albumin creatinine ratio (UACR) and creatinine clearance (CC) were calculated. Results: Serum cysteine c, BUN, urinary albumin and UACR were significantly lowered in both D-Bos. & D-Met when compared to the corresponding values in DN while urinary volume, urinary creatinine, CC and RBFV were significantly elevated but serum creatinine, NAG & RVR were significantly lowered in D-Bos. only. Conclusion: Bosentan and metformin treatment both have a renoprotective effect. Combined treatment showed better results. | ||||
| Keywords | ||||
| Bosentan; Diabetes; Endothelin; Metformin; Renal function | ||||
|
Statistics Article View: 269 PDF Download: 303 |
||||
